Adding pembrolizumab to THP improved pCR rates in patients with HER2-positive breast cancer in the phase 2 NeoHIP trial.

Josep M. Llovet, MD, PhD, describes the phase 3 LEAP-012 clinical study, including its methods, design, and enrollment criteria.

PDC*line Pharma, a clinical-stage biotech company developing a new class of immunotherapies for cancers, presented the ...

Bicycle Therapeutics presented data on zelenectide pevedotin, highlighting enhanced efficacy in cancer patients with NECTIN4 ...

Pembrolizumab plus fulvestrant provided disease control in 50% of patients with ER-positive, HER2-negative metastatic breast cancer.

An exploratory analysis of the KEYNOTE-522 study presented at the 2024 San Antonio Breast Cancer Symposium highlights ...

There is also pembrolizumab, but this agent has to be given intravenously, potentially exposing the patient to more toxicity ...

Based on the results of this study, current recommendations suggest that TNBC patients with tumors larger than 2 cm or with ...

The new promising data presented by Martin Forster, M.D., Ph.D., at the ESMO Immuno-Oncology (IO) Annual Congress 2024 ...

A study led by Roswell Park Comprehensive Cancer Center provides new insight into the complex interactions of the ...

Bicycle Therapeutics plc, a company specializing in developing therapeutic solutions based on its proprietary bicyclic peptide technology, revealed significant data updates across its zelenectide ...

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today ...